Sanofi and GSK launch trial for Covid-19 protein-based vaccine

French drugmaker Sanofi and its British peer GSK have began a medical trial for a protein-based Covid-19 vaccine candidate, as pharmaceutical corporations race to develop remedies in opposition to the coronavirus pandemic.

Sanofi and GSK stated in a joint assertion on Thursday they’d began the “Phase 1/2” trial for their adjuvanted Covid-19 vaccine, which they hope to make obtainable the world over.

This vaccine candidate makes use of the identical recombinant protein-based expertise as one in every of Sanofi’s seasonal influenza vaccines with GSK’s established pandemic adjuvant expertise.